** Hong Kong-listed Lepu Biopharma 2157.HK jumps 14.2% to HK$2.73; set for biggest one-day pct gain since Dec. 17, 2024
** Stock hits highest since Dec. 27, 2024; on track for fifth consecutive session of gains
** Co grants exclusive global rights to ArriVent BioPharma AVBP.O to develop and commercialize Lepu's novel antibody drug conjugate candidate MRG007, which is used to treat gastrointestinal cancers, outside of Greater China
** Lepu will get one-time upfront and near-term milestone payments of $47 mln
** Eligible to get up to $1.16 bln in development, regulatory and sales milestones and tiered royalties in high single-digit to low-teen percentages on net sales in Licensed Region
** AVBP rose 3.7% on Tuesday
** Lepu fell ~38% last year
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。